0001209191-14-077751.txt : 20141223
0001209191-14-077751.hdr.sgml : 20141223
20141223162528
ACCESSION NUMBER: 0001209191-14-077751
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20141223
FILED AS OF DATE: 20141223
DATE AS OF CHANGE: 20141223
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: BELLICUM PHARMACEUTICALS, INC
CENTRAL INDEX KEY: 0001358403
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
BUSINESS ADDRESS:
STREET 1: 2130 WEST HOLCOMBE BOULEVARD
STREET 2: SUITE 850
CITY: HOUSTON
STATE: TX
ZIP: 77030
BUSINESS PHONE: (832) 384-1100
MAIL ADDRESS:
STREET 1: 2130 WEST HOLCOMBE BOULEVARD
STREET 2: SUITE 850
CITY: HOUSTON
STATE: TX
ZIP: 77030
FORMER COMPANY:
FORMER CONFORMED NAME: BELLICUM PHARMACEUTICALS INC
DATE OF NAME CHANGE: 20060405
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Remeditex Ventures LLC
CENTRAL INDEX KEY: 0001627363
STATE OF INCORPORATION: TX
FISCAL YEAR END: 1231
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36783
FILM NUMBER: 141307205
BUSINESS ADDRESS:
STREET 1: 2101 CEDAR SPRINGS ROAD, SUITE 601
CITY: DALLAS
STATE: TX
ZIP: 75201
BUSINESS PHONE: (214) 506-2662
MAIL ADDRESS:
STREET 1: 2101 CEDAR SPRINGS ROAD, SUITE 601
CITY: DALLAS
STATE: TX
ZIP: 75201
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2014-12-23
0
0001358403
BELLICUM PHARMACEUTICALS, INC
BLCM
0001627363
Remeditex Ventures LLC
2101 CEDAR SPRINGS ROAD, SUITE 601
DALLAS
TX
75201
0
0
1
0
Common Stock
2014-12-23
4
C
0
1359297
A
1359297
D
Common Stock
2014-12-23
4
C
0
159444
A
1518741
D
Common Stock
2014-12-23
4
C
0
245299
A
1764040
D
Common Stock
2014-12-23
4
J
0
43563
0.00
A
1807603
D
Series B Convertible Preferred Stock
2014-12-23
4
C
0
2310806
0.00
D
Common Stock
1359297
0
D
Series C Convertible Preferred Stock
2014-12-23
4
C
0
271055
0.00
D
Common Stock
159444
0
D
Series C Convertible Preferred Stock
2014-12-23
4
C
0
417009
0.00
D
Common Stock
245299
0
D
The Series B Convertible Participating Preferred Stock converted into the Issuer's common stock on a 1.7-for-1 basis and had no expiration date.
Reflects 1.7-for-1 reverse stock split which became effective on December 5, 2014.
The Series C Convertible Preferred Stock converted into the Issuer's common stock on a 1.7-for-1 basis and had no expiration date.
On December 4, 2014, the Board of Directors of the Issuer declared a dividend payable to all holders of records of the Series B Convertible Participating Preferred Stock of the Issuer on December 16, 2014, payable in the form of cash or in shares of Common Stock of the Issuer, at the option of each holder. The dividends occurred in connection with the closing of the Issuer's public offering. The Reporting Person elected to receive the shares of Common Stock.
By: /s/ John Creecy, CEO
2014-12-23